Autoinflammatory & rare systemic diseases
Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults
Authors' conclusion
The incidence of IgG4-RD is similar to that of systemic rheumatic diseases such as ANCA-associated vasculitis and systemic sclerosis but may be increasing as familiarity with this diagnosis grows.
Study context
- Population
- Commercially insured adults in the USA, Optum Clinformatics Data Mart Database, 2009–2021 (mean age 56.5 years; 57.6% female; 66% White)524 igG4-related disease (IgG4-RD) cases identified
- Participants
- 515 vs 5,160
- Exposure
- IgG4-RD vs matched non-IgG4-RD population
- IgG4-RDn = 515
- Comparatorsn = 5,160reference
- Outcome
- Incidence rate and prevalence of IgG4-RD, standardised to the US population by age and sex
- Follow-up
- 2015–2019
Methodological detailsclaims-based, validated algorithm, standardised to US population by age and sex, matched 1:10 on age, sex, race/ethnicity and encounter date, Cox proportional hazards models
- Claims-based
- Validated algorithm
- Standardised to US population by age and sex
- Matched 1:10 on age, sex, race/ethnicity and encounter date
- Cox proportional hazards models
Main finding
As reported in the abstract
Incidence and prevalence of IgG4-RD
Incidence, 2015
0.78 per 100 000 person-years
Incidence, 2019
1.39 per 100 000 person-years
Point prevalence on 1 January 2019
5.3/100 000 persons
Observational data: associations, not effects.
Further findings
| Outcome | IgG4-RD | Comparators | aHR (95% CI) | |
|---|---|---|---|---|
| Mortality · During follow-up | mortality rate 3.42 /100 person-years | mortality rate 1.46 /100 person-years | 2.51 (1.76–3.56) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
- Mortality: matched 1:10
Original publication
Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults. Ann Rheum Dis. Published 3 May 2023. doi:10. 1136/ ard-2023-223950
Composed by AI from the published abstract and checked against it. How Briefs are made →